Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule: Weeks 14: Inject 20 units (0.2 mL) one time per week Weeks 58: Inject 40 units (0.4 mL) one time per week Weeks 912: Inject 70 units (0.7 mL) one time per week Weeks 1316: Inject 90 units (0.9 mL) one time per week Weeks 1720: Inject 120 units (1.2 mL) one time per week Week 21+: Inject 140 units (1.4 mL) one time per week Dosing may deviate from this pattern to accommodate patient-specific needs
Its ability to be delivered through multiple routes may stem from a possible affinity for a peptide transporter, hPepT1, that occurs in the gastrointestinal tract.3 Researchers have also administered KPV topically or transdermally through technologies such as ionophoresis, which uses small electrical currents to drive the medication through the skin.4 There are even battery-integrated patches that use this technology.5 That being said, subcutaneous injection is likely the most rapid form of KPV drug delivery for systemic benefits, as well as the form you have the best chances of getting for your own use
Wegovy is a weight loss injection that is taken once a week, containing semaglutide
Without FDA oversight, you cannot always trust what is in the vial
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
